MI-538是一种menin和MLL融合蛋白相互作用的抑制剂，IC50值为 21 nM。

MI-538 is an interaction between menin and MLL fusion proteins inhibitor(IC50 of 21 nM).

Treatment with MI-538 results in strong down regulation of expression of Hoxa9 and Meis1 genes. About 100 nM 27 was sufficient to reduce by ~50% Hoxa9 expression in MLL-AF9 cells, and even more pronounced effect was seen on Meis1 expression.

Treatment with MI-538 results in a pronounced, about 80%, reduction in the MV4;11 tumor volume, without causing substantial signs of toxicity reflected by less than 10% reduction of the body weight.

1857417-10-7

C27H25F3N8OS

566.6

DMSO:95 mg/mL (167.67 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years